In a research report sent to investors on Thursday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a …
In a research report released today, MLV analyst George Zavoico reiterated a Buy rating on Peregrine Pharmaceuticals (NASDAQ:PPHM) with a $3.50 price target, …
In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $5 price …
